{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,21]],"date-time":"2026-05-21T19:26:14Z","timestamp":1779391574177,"version":"3.53.1"},"reference-count":61,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2023,1,30]],"date-time":"2023-01-30T00:00:00Z","timestamp":1675036800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2023,1,30]],"date-time":"2023-01-30T00:00:00Z","timestamp":1675036800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Drugs Aging"],"published-print":{"date-parts":[[2023,3]]},"DOI":"10.1007\/s40266-022-01005-1","type":"journal-article","created":{"date-parts":[[2023,1,30]],"date-time":"2023-01-30T16:15:34Z","timestamp":1675095334000},"page":"263-272","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["A Proactive Approach to Prevent Hematopoietic Exhaustion During Cancer Chemotherapy in Older Patients: Temporary Cell-Cycle Arrest"],"prefix":"10.1007","volume":"40","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3103-2892","authenticated-orcid":false,"given":"Lodovico","family":"Balducci","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claire","family":"Falandry","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alan","family":"List","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,1,30]]},"reference":[{"issue":"11","key":"1005_CR1","doi-asserted-by":"publisher","first-page":"885","DOI":"10.2165\/11595100-000000000-00000","volume":"28","author":"E Quoix","year":"2011","unstructured":"Quoix E. Optimal pharmacotherapeutic strategies for elderly patients with advanced non-small cell lung cancer. Drugs Aging. 2011;28(11):885\u201394. https:\/\/doi.org\/10.2165\/11595100-000000000-00000.","journal-title":"Drugs Aging"},{"issue":"9","key":"1005_CR2","first-page":"5007","volume":"34","author":"C Falandry","year":"2014","unstructured":"Falandry C, Krakowski I, Cur\u00e9 H, et al. Granulocyte-colony-stimulating factor in elderly patients receiving chemotherapy for breast and gynaecological cancers: results of a French survey. Anticancer Res. 2014;34(9):5007\u201315.","journal-title":"Anticancer Res"},{"key":"1005_CR3","doi-asserted-by":"publisher","unstructured":"Dhillon S. Trilaciclib: first approval. Drugs. 2021;81(7):867\u201374. https:\/\/doi.org\/10.1007\/s40265-021-01508-y(this article explains the mechanism of action of trilaciclib and the potential limitation of its use)","DOI":"10.1007\/s40265-021-01508-y"},{"key":"1005_CR4","doi-asserted-by":"publisher","unstructured":"Andric Z, Ceric T, Turic M, et al. A phase I B study of the dual MDMX\/MDM2 inhibitor for prevention of chemotherapy induced myelosuppression. Presented at the virtual European Society of Medical Oncology Congress September 16 2021 #1654 AP. Ann Oncol. 2021;32(Suppl_5):S1164\u201374. https:\/\/doi.org\/10.1016\/annonc\/annonc68","DOI":"10.1016\/annonc\/annonc68"},{"issue":"4","key":"1005_CR5","doi-asserted-by":"publisher","first-page":"1323","DOI":"10.1007\/s00520-017-3959-2","volume":"26","author":"JJ Kirshner","year":"2018","unstructured":"Kirshner JJ, McDonald MC 3rd, Kruter K, et al. NOLAN: a randomized, phase 2 study to estimate the effect of prophylactic naproxen or loratadine vs no prophylactic treatment on bone pain in patients with early-stage breast cancer receiving chemotherapy and pegfilgrastim. Support Care Cancer. 2018;26(4):1323\u201334. https:\/\/doi.org\/10.1007\/s00520-017-3959-2. (Epub 2017 Nov 16).","journal-title":"Support Care Cancer"},{"issue":"6893","key":"1005_CR6","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1038\/418025a","volume":"418","author":"SH Orkin","year":"2002","unstructured":"Orkin SH, Morrison SJ. Stem-cell competition. Nature. 2002;418(6893):25\u20137. https:\/\/doi.org\/10.1038\/418025a.","journal-title":"Nature"},{"key":"1005_CR7","doi-asserted-by":"publisher","first-page":"1219","DOI":"10.1038\/s41588-020-00710-0","volume":"52","author":"KL Bolton","year":"2020","unstructured":"Bolton KL, Ptashkin RN, Gao T, Braunstein L, Devlin SM, Kelly D, et al. Cancer therapy shapes the fitness landscape of clonal hematopoiesis. Nat Genet. 2020;52:1219\u201326.","journal-title":"Nat Genet"},{"issue":"3","key":"1005_CR8","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1200\/JOP.19.00652","volume":"16","author":"TJ Brown","year":"2020","unstructured":"Brown TJ, Gupta A. Management of cancer therapy-associated oral mucositis. JCO Oncol Pract. 2020;16(3):103\u20139. https:\/\/doi.org\/10.1200\/JOP.19.00652.","journal-title":"JCO Oncol Pract."},{"key":"1005_CR9","doi-asserted-by":"publisher","unstructured":"Worthington HV, Clarkson JE, Bryan G, et al. Interventions for preventing oral mucositis for patients with cancer receiving treatment. Cochrane Database Syst Rev. 2011;2011(4):CD000978. https:\/\/doi.org\/10.1002\/14651858.CD000978.pub5.","DOI":"10.1002\/14651858.CD000978.pub5"},{"issue":"2","key":"1005_CR10","doi-asserted-by":"publisher","first-page":"e50","DOI":"10.1016\/S1470-2045(12)70553-3","volume":"14","author":"R Paus","year":"2013","unstructured":"Paus R, Haslam IS, Sharov AA, Botchkarev VA. Pathobiology of chemotherapy-induced hair loss. Lancet Oncol. 2013;14(2):e50\u20139. https:\/\/doi.org\/10.1016\/S1470-2045(12)70553-3.","journal-title":"Lancet Oncol"},{"key":"1005_CR11","doi-asserted-by":"publisher","unstructured":"Lai AY, Sorrentino JA, Dragnev KH, et al. CDK4\/6 inhibition enhances antitumor efficacy of chemotherapy and immune checkpoint inhibitor combinations in preclinical models and enhances T-cell activation in patients with SCLC receiving chemotherapy. J Immunother Cancer. 2020;8(2):e000847. https:\/\/doi.org\/10.1136\/jitc-2020-000847.","DOI":"10.1136\/jitc-2020-000847"},{"key":"1005_CR12","doi-asserted-by":"publisher","first-page":"6207","DOI":"10.2147\/CMAR.S313045","volume":"13","author":"M Hussein","year":"2021","unstructured":"Hussein M, Maglakelidze M, Richards DA, et al. Myeloprotective effects of trilaciclib among patients with small cell lung cancer at increased risk of chemotherapy-induced myelosuppression: pooled results from three phase 2, randomized, double-blind, placebo-controlled studies. Cancer Manag Res. 2021;13:6207\u201318. https:\/\/doi.org\/10.2147\/CMAR.S313045.","journal-title":"Cancer Manag Res."},{"issue":"10","key":"1005_CR13","doi-asserted-by":"publisher","first-page":"2564","DOI":"10.1158\/2159-8290.CD-20-1540","volume":"11","author":"M Heckler","year":"2021","unstructured":"Heckler M, Ali LR, Clancy-Thompson E, et al. Inhibition of CDK4\/6 promotes CD8 T-cell memory formation. Cancer Discov. 2021;11(10):2564\u201381. https:\/\/doi.org\/10.1158\/2159-8290.CD-20-1540. (Epub 2021 May 3).","journal-title":"Cancer Discov"},{"key":"1005_CR14","doi-asserted-by":"publisher","unstructured":"Zhou X, Singh M, Sanz Santos G, et al. Pharmacological activation of p53 triggers viral mimicry response thereby abolishing tumor immune evasion and promoting anti-tumor immunity. Cancer Discov. 2021. https:\/\/doi.org\/10.1158\/2159-8290.CD-20-1741. Epub ahead of print.","DOI":"10.1158\/2159-8290.CD-20-1741"},{"key":"1005_CR15","unstructured":"Available from: https:\/\/cancercontrol.cancer.gov\/ocs\/statistics#footnote1. Accessed 13 July 2022"},{"key":"1005_CR16","doi-asserted-by":"publisher","unstructured":"Arai H, Ouchi Y, Yokode M, Ito H, et al. Members of Subcommittee for Aging. Toward the realization of a better aged society: messages from gerontology and geriatrics. Geriatr Gerontol Int. 2012;12(1):16\u201322. https:\/\/doi.org\/10.1111\/j.1447-0594.2011.00776.x.","DOI":"10.1111\/j.1447-0594.2011.00776.x"},{"issue":"1","key":"1005_CR17","doi-asserted-by":"publisher","first-page":"174","DOI":"10.1186\/s12877-021-02036-w","volume":"21","author":"E Akatsuka","year":"2021","unstructured":"Akatsuka E, Tadaka E. Development of a resilience scale for oldest-old age (RSO). BMC Geriatr. 2021;21(1):174. https:\/\/doi.org\/10.1186\/s12877-021-02036-w.","journal-title":"BMC Geriatr"},{"key":"1005_CR18","doi-asserted-by":"publisher","unstructured":"Jia H, Lubetkin EI. Life expectancy and active life expectancy by disability status in older U.S. adults. PLoS One. 2020;15(9):e0238890. https:\/\/doi.org\/10.1371\/journal.pone.0238890.","DOI":"10.1371\/journal.pone.0238890"},{"issue":"10","key":"1005_CR19","doi-asserted-by":"publisher","first-page":"3113","DOI":"10.3390\/jcm9103113","volume":"9","author":"AM Fritzen","year":"2020","unstructured":"Fritzen AM, Andersen SP, Qadri KAN, et al. Effect of aerobic exercise training and deconditioning on oxidative capacity and muscle mitochondrial enzyme machinery in young and elderly individuals. J Clin Med. 2020;9(10):3113. https:\/\/doi.org\/10.3390\/jcm9103113.","journal-title":"J Clin Med"},{"issue":"2","key":"1005_CR20","doi-asserted-by":"publisher","first-page":"233","DOI":"10.3109\/0284186X.2012.744142","volume":"52","author":"L Balducci","year":"2013","unstructured":"Balducci L, Fossa SD. Rehabilitation of older cancer patients. Acta Oncol. 2013;52(2):233\u20138. https:\/\/doi.org\/10.3109\/0284186X.2012.744142.","journal-title":"Acta Oncol"},{"key":"1005_CR21","unstructured":"The reasons some people refuse chemo. https:\/\/www.verywellhealth.com. Accessed 6 Jan 2023."},{"issue":"4","key":"1005_CR22","doi-asserted-by":"publisher","first-page":"225","DOI":"10.3816\/SCT.2005.n.015","volume":"2","author":"L Balducci","year":"2005","unstructured":"Balducci L. Supportive care of elderly patients with cancer. Support Cancer Ther. 2005;2(4):225\u20138. https:\/\/doi.org\/10.3816\/SCT.2005.n.015.","journal-title":"Support Cancer Ther."},{"key":"1005_CR23","doi-asserted-by":"publisher","unstructured":"Balducci L, Goetz-Parten D, Steinman MA. Polypharmacy and the management of the older cancer patient. Ann Oncol. 2013;24 Suppl. 7(Suppl 7.):vii36\u201340. https:\/\/doi.org\/10.1093\/annonc\/mdt266","DOI":"10.1093\/annonc\/mdt266"},{"key":"1005_CR24","doi-asserted-by":"publisher","unstructured":"Li D, Sun CL, Kim H, et al. Geriatric Assessment-Driven Intervention (GAIN) on chemotherapy-related toxic effects in older adults with cancer: a randomized clinical trial. JAMA Oncol. 2021;7(11):e214158. https:\/\/doi.org\/10.1001\/jamaoncol.2021.4158(Epub 2021 Nov 18).","DOI":"10.1001\/jamaoncol.2021.4158"},{"issue":"10314","key":"1005_CR25","doi-asserted-by":"publisher","first-page":"1894","DOI":"10.1016\/S0140-6736(21)01789-X","volume":"398","author":"SG Mohile","year":"2021","unstructured":"Mohile SG, Mohamed MR, Xu H, Culakova E, et al. Evaluation of geriatric assessment and management on the toxic effects of cancer treatment (GAP70+): a cluster-randomised study. Lancet. 2021;398(10314):1894\u2013904. https:\/\/doi.org\/10.1016\/S0140-6736(21)01789-X. (Epub 2021 Nov 3).","journal-title":"Lancet"},{"issue":"1","key":"1005_CR26","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1186\/s12877-021-02722-9","volume":"22","author":"KF Boreskie","year":"2022","unstructured":"Boreskie KF, Hay JL, Boreskie PE, Arora RC, Duhamel TA. Frailty-aware care: giving value to frailty assessment across different healthcare settings. BMC Geriatr. 2022;22(1):13. https:\/\/doi.org\/10.1186\/s12877-021-02722-9.","journal-title":"BMC Geriatr"},{"issue":"22","key":"1005_CR27","doi-asserted-by":"publisher","first-page":"2326","DOI":"10.1200\/JCO.2018.78.8687","volume":"36","author":"SG Mohile","year":"2018","unstructured":"Mohile SG, Dale W, Somerfield MR, et al. Practical assessment and management of vulnerabilities in older patients receiving chemotherapy: ASCO guideline for geriatric oncology. J Clin Oncol. 2018;36(22):2326\u201347. https:\/\/doi.org\/10.1200\/JCO.2018.78.8687. (Epub 2018 May 21).","journal-title":"J Clin Oncol"},{"issue":"24","key":"1005_CR28","doi-asserted-by":"publisher","first-page":"2595","DOI":"10.1200\/JCO.2013.54.8347","volume":"32","author":"H Wildiers","year":"2014","unstructured":"Wildiers H, Heeren P, Puts M, et al. International Society of Geriatric Oncology consensus on geriatric assessment in older patients with cancer. J Clin Oncol. 2014;32(24):2595\u2013603. https:\/\/doi.org\/10.1200\/JCO.2013.54.8347.","journal-title":"J Clin Oncol"},{"key":"1005_CR29","doi-asserted-by":"publisher","unstructured":"Hurria A, Wildes T, Blair SL, et al. Senior adult oncology, version 2.2014: clinical practice guidelines in oncology. J Natl Compr Canc Netw. 2014;12(1):82\u2013126. https:\/\/doi.org\/10.6004\/jnccn.2014.0009","DOI":"10.6004\/jnccn.2014.0009"},{"issue":"16","key":"1005_CR30","doi-asserted-by":"publisher","first-page":"2264","DOI":"10.1016\/s0959-8049(03)00662-2","volume":"39","author":"L Repetto","year":"2003","unstructured":"Repetto L, Biganzoli L, Koehne CH, et al. EORTC Cancer in the Elderly Task Force guidelines for the use of colony-stimulating factors in elderly patients with cancer. Eur J Cancer. 2003;39(16):2264\u201372. https:\/\/doi.org\/10.1016\/s0959-8049(03)00662-2.","journal-title":"Eur J Cancer"},{"issue":"13","key":"1005_CR31","doi-asserted-by":"publisher","first-page":"3377","DOI":"10.1002\/cncr.26646","volume":"118","author":"M Extermann","year":"2012","unstructured":"Extermann M, Boler I, Reich RR, et al. Predicting the risk of chemotherapy toxicity in older patients: the Chemotherapy Risk Assessment Scale for High-Age Patients (CRASH) score. Cancer. 2012;118(13):3377\u201386. https:\/\/doi.org\/10.1002\/cncr.26646. (Epub 2011 Nov 9).","journal-title":"Cancer"},{"issue":"20","key":"1005_CR32","doi-asserted-by":"publisher","first-page":"2366","DOI":"10.1200\/JCO.2015.65.4327","volume":"34","author":"A Hurria","year":"2016","unstructured":"Hurria A, Mohile S, Gajra A, et al. Validation of a prediction tool for chemotherapy toxicity in older adults with cancer. J Clin Oncol. 2016;34(20):2366\u201371. https:\/\/doi.org\/10.1200\/JCO.2015.65.4327. (Epub 2016 May 16).","journal-title":"J Clin Oncol"},{"issue":"9","key":"1005_CR33","doi-asserted-by":"publisher","first-page":"2075","DOI":"10.3390\/cancers14092075","volume":"14","author":"H Suto","year":"2022","unstructured":"Suto H, Inui Y, Okamura A. Validity of the Cancer and Aging Research Group predictive tool in older Japanese patients. Cancers (Basel). 2022;14(9):2075. https:\/\/doi.org\/10.3390\/cancers14092075.","journal-title":"Cancers (Basel)."},{"issue":"10","key":"1005_CR34","doi-asserted-by":"publisher","first-page":"576","DOI":"10.1038\/s41574-018-0059-4","volume":"14","author":"C Franceschi","year":"2018","unstructured":"Franceschi C, Garagnani P, Parini P, et al. Inflammaging: a new immune-metabolic viewpoint for age-related diseases. Nat Rev Endocrinol. 2018;14(10):576\u201390. https:\/\/doi.org\/10.1038\/s41574-018-0059-4.","journal-title":"Nat Rev Endocrinol"},{"issue":"9","key":"1005_CR35","doi-asserted-by":"publisher","first-page":"5732","DOI":"10.21037\/tcr.2020.03.39","volume":"9","author":"HB Muss","year":"2020","unstructured":"Muss HB, Smitherman A, Wood WA, et al. p16 a biomarker of aging and tolerance for cancer therapy. Transl Cancer Res. 2020;9(9):5732\u201342. https:\/\/doi.org\/10.21037\/tcr.2020.03.39.","journal-title":"Transl Cancer Res."},{"issue":"1","key":"1005_CR36","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1186\/s13059-019-1824-y","volume":"20","author":"CG Bell","year":"2019","unstructured":"Bell CG, Lowe R, Adams PD, et al. DNA methylation aging clocks: challenges and recommendations. Genome Biol. 2019;20(1):249. https:\/\/doi.org\/10.1186\/s13059-019-1824-y.","journal-title":"Genome Biol"},{"issue":"19","key":"1005_CR37","doi-asserted-by":"publisher","first-page":"4547","DOI":"10.1002\/cncr.24490","volume":"115","author":"A Tucci","year":"2009","unstructured":"Tucci A, Ferrari S, Bottelli C. A comprehensive geriatric assessment is more effective than clinical judgment to identify elderly diffuse large cell lymphoma patients who benefit from aggressive therapy. Cancer. 2009;115(19):4547\u201353. https:\/\/doi.org\/10.1002\/cncr.24490.","journal-title":"Cancer"},{"issue":"9","key":"1005_CR38","doi-asserted-by":"publisher","first-page":"897","DOI":"10.1007\/s00277-010-0956-7","volume":"89","author":"T Hirakawa","year":"2010","unstructured":"Hirakawa T, Yamaguchi H, Yokose N, et al. Importance of maintaining the relative dose intensity of CHOP-like regimens combined with rituximab in patients with diffuse large B-cell lymphoma. Ann Hematol. 2010;89(9):897\u2013904. https:\/\/doi.org\/10.1007\/s00277-010-0956-7. (Epub 2010 Apr 23).","journal-title":"Ann Hematol"},{"issue":"1","key":"1005_CR39","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1056\/NEJM198101013040103","volume":"304","author":"G Bonadonna","year":"1981","unstructured":"Bonadonna G, Valagussa P. Dose-response effect of adjuvant chemotherapy in breast cancer. N Engl J Med. 1981;304(1):10\u20135. https:\/\/doi.org\/10.1056\/NEJM198101013040103.","journal-title":"N Engl J Med"},{"issue":"19","key":"1005_CR40","doi-asserted-by":"publisher","first-page":"3187","DOI":"10.1200\/JCO.2006.06.4451","volume":"24","author":"TJ Smith","year":"2006","unstructured":"Smith TJ, Khatcheressian J, Lyman GH, et al. 2006 update of recommendations for the use of white blood cell growth factors: an evidence-based clinical practice guideline. J Clin Oncol. 2006;24(19):3187\u2013205. https:\/\/doi.org\/10.1200\/JCO.2006.06.4451. (Epub 2006 May 8).","journal-title":"J Clin Oncol"},{"issue":"17","key":"1005_CR41","doi-asserted-by":"publisher","first-page":"2914","DOI":"10.1200\/JCO.2009.25.8723","volume":"28","author":"GH Lyman","year":"2010","unstructured":"Lyman GH, Dale DC, Wolff DA, et al. Acute myeloid leukemia or myelodysplastic syndrome in randomized controlled clinical trials of cancer chemotherapy with granulocyte colony-stimulating factor: a systematic review. J Clin Oncol. 2010;28(17):2914\u201324. https:\/\/doi.org\/10.1200\/JCO.2009.25.8723. (Epub 2010 Apr 12).","journal-title":"J Clin Oncol"},{"issue":"8","key":"1005_CR42","doi-asserted-by":"publisher","first-page":"1197","DOI":"10.1182\/bloodadvances.2018030387","volume":"3","author":"J Bohlius","year":"2019","unstructured":"Bohlius J, Bohlke K, Castelli R, et al. Management of cancer-associated anemia with erythropoiesis-stimulating agents: ASCO\/ASH clinical practice guideline update. Blood Adv. 2019;3(8):1197\u2013210. https:\/\/doi.org\/10.1182\/bloodadvances.2018030387.","journal-title":"Blood Adv"},{"issue":"7","key":"1005_CR43","doi-asserted-by":"publisher","first-page":"801","DOI":"10.1182\/blood.2019004017","volume":"136","author":"JA Gilreath","year":"2020","unstructured":"Gilreath JA, Rodgers GM. How I treat cancer-associated anemia. Blood. 2020;136(7):801\u201313. https:\/\/doi.org\/10.1182\/blood.2019004017.","journal-title":"Blood"},{"issue":"4","key":"1005_CR44","doi-asserted-by":"publisher","first-page":"242","DOI":"10.1053\/j.seminhematol.2008.06.001","volume":"45","author":"L Ferrucci","year":"2008","unstructured":"Ferrucci L, Balducci L. Anemia of aging: the role of chronic inflammation and cancer. Semin Hematol. 2008;45(4):242\u20139. https:\/\/doi.org\/10.1053\/j.seminhematol.2008.06.001.","journal-title":"Semin Hematol"},{"issue":"3","key":"1005_CR45","doi-asserted-by":"publisher","first-page":"891","DOI":"10.1111\/jgs.17565","volume":"70","author":"J Guralnik","year":"2022","unstructured":"Guralnik J, Ershler W, Artz A, et al. Anemia: etiology, health consequences, and diagnostic criteria. J Am Geriatr Soc. 2022;70(3):891\u20139. https:\/\/doi.org\/10.1111\/jgs.17565. (Epub 2021 Nov 19).","journal-title":"J Am Geriatr Soc"},{"issue":"10","key":"1005_CR46","doi-asserted-by":"publisher","first-page":"2297","DOI":"10.1111\/jgs.16657","volume":"68","author":"EM Simonsick","year":"2020","unstructured":"Simonsick EM, Patel KV, Schrack JA, Ferrucci L. Fatigability as a predictor of subclinical and clinical anemia in well-functioning older adults. J Am Geriatr Soc. 2020;68(10):2297\u2013302. https:\/\/doi.org\/10.1111\/jgs.16657. (Epub 2020 Jul 3).","journal-title":"J Am Geriatr Soc"},{"issue":"12","key":"1005_CR47","doi-asserted-by":"publisher","first-page":"1389","DOI":"10.1093\/gerona\/63.12.1389","volume":"63","author":"SE Hardy","year":"2008","unstructured":"Hardy SE, Studenski SA. Fatigue and function over 3 years among older adults. J Gerontol A Biol Sci Med Sci. 2008;63(12):1389\u201392. https:\/\/doi.org\/10.1093\/gerona\/63.12.1389.","journal-title":"J Gerontol A Biol Sci Med Sci"},{"issue":"10","key":"1005_CR48","doi-asserted-by":"publisher","first-page":"1910","DOI":"10.1111\/j.1532-5415.2008.01957.x","volume":"56","author":"SE Hardy","year":"2008","unstructured":"Hardy SE, Studenski SA. Fatigue predicts mortality in older adults. J Am Geriatr Soc. 2008;56(10):1910\u20134. https:\/\/doi.org\/10.1111\/j.1532-5415.2008.01957.x. (Epub 2008 Sep 22).","journal-title":"J Am Geriatr Soc"},{"key":"1005_CR49","doi-asserted-by":"publisher","unstructured":"The Lancet Haematology. Updates on blood transfusion guidelines. Lancet Haematol. 2016;3(12):e547. https:\/\/doi.org\/10.1016\/S2352-3026(16)30172-7.","DOI":"10.1016\/S2352-3026(16)30172-7"},{"issue":"5","key":"1005_CR50","doi-asserted-by":"publisher","first-page":"437","DOI":"10.1080\/17474086.2021.1924053","volume":"14","author":"H Al-Samkari","year":"2021","unstructured":"Al-Samkari H, Soff GA. Clinical challenges and promising therapies for chemotherapy-induced thrombocytopenia. Expert Rev Hematol. 2021;14(5):437\u201348. https:\/\/doi.org\/10.1080\/17474086.2021.1924053. (Epub 2021 May 13).","journal-title":"Expert Rev Hematol"},{"issue":"4","key":"1005_CR51","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1177\/1078155207077335","volume":"13","author":"G Richardson","year":"2007","unstructured":"Richardson G, Dobish R. Chemotherapy induced diarrhea. J Oncol Pharm Pract. 2007;13(4):181\u201398. https:\/\/doi.org\/10.1177\/1078155207077335.","journal-title":"J Oncol Pharm Pract"},{"issue":"6","key":"1005_CR52","doi-asserted-by":"publisher","first-page":"606","DOI":"10.1001\/jama.2016.21038","volume":"317","author":"HS Rugo","year":"2017","unstructured":"Rugo HS, Klein P, Melin SA, et al. Association between use of a scalp cooling device and alopecia after chemotherapy for breast cancer. JAMA. 2017;317(6):606\u201314. https:\/\/doi.org\/10.1001\/jama.2016.21038.","journal-title":"JAMA"},{"issue":"3","key":"1005_CR53","doi-asserted-by":"publisher","first-page":"527","DOI":"10.1007\/s10549-017-4204-x","volume":"163","author":"GM Kim","year":"2017","unstructured":"Kim GM, Kim S, Park HS, et al. Chemotherapy-induced irreversible alopecia in early breast cancer patients. Breast Cancer Res Treat. 2017;163(3):527\u201333. https:\/\/doi.org\/10.1007\/s10549-017-4204-x. (Epub 2017 Mar 21).","journal-title":"Breast Cancer Res Treat"},{"issue":"1","key":"1005_CR54","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1038\/ncb2641","volume":"15","author":"PA Muller","year":"2013","unstructured":"Muller PA, Vousden KH. p53 mutations in cancer. Nat Cell Biol. 2013;15(1):2\u20138. https:\/\/doi.org\/10.1038\/ncb2641.","journal-title":"Nat Cell Biol"},{"issue":"10","key":"1005_CR55","doi-asserted-by":"publisher","first-page":"1613","DOI":"10.1093\/annonc\/mdz278","volume":"30","author":"JM Weiss","year":"2019","unstructured":"Weiss JM, Csoszi T, Maglakelidze M, et al. Myelopreservation with the CDK4\/6 inhibitor trilaciclib in patients with small-cell lung cancer receiving first-line chemotherapy: a phase Ib\/randomized phase II trial. Ann Oncol. 2019;30(10):1613\u201321. https:\/\/doi.org\/10.1093\/annonc\/mdz278.","journal-title":"Ann Oncol"},{"key":"1005_CR56","doi-asserted-by":"publisher","unstructured":"Daniel D, Kuchava V, Bondarenko I, et al. Trilaciclib prior to chemotherapy and atezolizumab in patients with newly diagnosed extensive-stage small cell lung cancer: a multicentre, randomised, double-blind, placebo-controlled phase II trial. Int J Cancer. 2020;148(10):2557\u201370. https:\/\/doi.org\/10.1002\/ijc.33453. Epub ahead of print.","DOI":"10.1002\/ijc.33453"},{"issue":"1","key":"1005_CR57","doi-asserted-by":"publisher","first-page":"350","DOI":"10.1007\/s12325-020-01538-0","volume":"38","author":"LL Hart","year":"2021","unstructured":"Hart LL, Ferrarotto R, Andric ZG, et al. Myelopreservation with trilaciclib in patients receiving topotecan for small cell lung cancer: results from a randomized, double-blind, placebo-controlled phase II study. Adv Ther. 2021;38(1):350\u201365. https:\/\/doi.org\/10.1007\/s12325-020-01538-0. (Epub 2020 Oct 29).","journal-title":"Adv Ther"},{"issue":"5","key":"1005_CR58","doi-asserted-by":"publisher","first-page":"449","DOI":"10.1016\/j.cllc.2021.03.010","volume":"22","author":"J Weiss","year":"2021","unstructured":"Weiss J, Goldschmidt J, Andric Z, et al. Effects of trilaciclib on chemotherapy-induced myelosuppression and patient-reported outcomes in patients with extensive-stage small cell lung cancer: pooled results from three phase II randomized, double-blind, placebo-controlled studies. Clin Lung Cancer. 2021;22(5):449\u201360. https:\/\/doi.org\/10.1016\/j.cllc.2021.03.010. (Epub 2021 Mar 26).","journal-title":"Clin Lung Cancer"},{"key":"1005_CR59","unstructured":"Gherardini J. Portland, OR May 21, 2022. The meeting took place at the\nConvention Center"},{"key":"1005_CR60","unstructured":"Gheradini, et al. Temporary cell cycle arrest by ALRN-6924 selectively protects human scalp hair follicles and their epithelial cells from taxane-induced toxicity. Presented at the 2022 Society for Investigative Dermatology Annual Meeting"},{"issue":"2","key":"1005_CR61","doi-asserted-by":"publisher","first-page":"e29","DOI":"10.1002\/bjs.10053","volume":"103","author":"JR Aunan","year":"2016","unstructured":"Aunan JR, Watson MM, Hagland HR, S\u00f8reide K. Molecular and biological hallmarks of ageing. Br J Surg. 2016;103(2):e29-46. https:\/\/doi.org\/10.1002\/bjs.10053.","journal-title":"Br J Surg"}],"container-title":["Drugs & Aging"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40266-022-01005-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40266-022-01005-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40266-022-01005-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,3,27]],"date-time":"2023-03-27T02:58:33Z","timestamp":1679885913000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40266-022-01005-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,1,30]]},"references-count":61,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2023,3]]}},"alternative-id":["1005"],"URL":"https:\/\/doi.org\/10.1007\/s40266-022-01005-1","relation":{},"ISSN":["1170-229X","1179-1969"],"issn-type":[{"value":"1170-229X","type":"print"},{"value":"1179-1969","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,1,30]]},"assertion":[{"value":"27 December 2022","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 January 2023","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"No external funding was used in the preparation of this article.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"Lodovico Balducci is a consultant for Aileron. Alan List is a consultant for Aileron. Claire Falandry has no conflicts of interest that are directly relevant to the content of this article.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest\/competing interest"}},{"value":"No ethics approval was needed for a review article.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"This is a review article and did not require the participation of human subjects.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Not applicable.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"No dataset was generated or analyzed during the current study.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Availability of data and material"}},{"value":"Not applicable.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code availability"}},{"value":"LB generated the idea of this review and wrote the original draft. CF reviewed and revised the geriatric portion. Alan List reviewed and revised the information related to growth factors, ALRN-6924, and trilaciclib, and highlighted the proactive approach that is the most novel aspect of this review.","order":9,"name":"Ethics","group":{"name":"EthicsHeading","label":"Authors\u2019 Contributions"}}]}}